%0 Journal Article %A Tien Nguyen %A Melvin Churchill %A Robert Levin %A Guillermo Valenzuela %A Joseph F. Merola %A Alexis Ogdie %A Ana-Maria Orbai %A Jose U. Scher %A Arthur Kavanaugh %A Farid Kianifard %A Chauncy Rollins %A Renato Calheiros %A Olivier Chambenoit %T Secukinumab in US Biologic-Naive Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study %D 2022 %R 10.3899/jrheum.210912 %J The Journal of Rheumatology %P jrheum.210912 %X Objective To evaluate secukinumab 300 mg and 150 mg vs placebo in a US-only population of biologic-naive patients with psoriatic arthritis (PsA). Methods CHOICE was a randomized, double-blind, controlled trial conducted in the United States. Biologic-naive patients with PsA and psoriasis were randomized 2:2:1 to secukinumab 300 mg (n = 103), secukinumab 150 mg (n = 103), or placebo (n = 52). The primary objective was to show superiority of secukinumab 300 mg vs placebo in ACR20 response at week 16. Additional objectives included the effect of secukinumab on dactylitis, enthesitis, psoriasis, and safety. Results ACR20 response rates at week 16 were higher with secukinumab 300 mg than with placebo (51.5% vs 23.1%; odds ratio, 3.51 [95% CI: 1.65, 7.45]; P = .0011). Secukinumab 300 mg also led to greater ACR50/70 responses and improvements in other variables vs placebo. Responses were generally sustained over time. Patients with inadequate response to secukinumab 150 mg at weeks 16, 28, or 40 who received dose escalation to 300 mg experienced improved clinical response after uptitration. The most common adverse events were upper respiratory tract infections and diarrhea. No inflammatory bowel disease was reported or new safety signals observed. Conclusion Secukinumab 300 mg led to rapid and significant improvements over placebo in symptoms of PsA in this heavier population of US-only biologic-naive patients. Findings were consistent with previous studies and suggest that secukinumab 300 mg is a safe and efficacious first-line biologic treatment for patients with PsA. %U https://www.jrheum.org/content/jrheum/early/2022/04/11/jrheum.210912.full.pdf